Booming biotech market in India, now worth $2.4 billion, boosted by govt initiatives

16 April 2010

As a result of a large pool of scientific talent, world-class information technology industry, and vibrant pharmaceutical sector, the Indian biotech industry has stupendously grown over the past few years, according to a news report added to the offering of Research and Markets.

During the 2005-2009 fiscal years, the industry witnessed an impressive compound annual growth rate (CAGR) of around 26.5% and generated total revenue of 121.4 billion rupees ($2.4 billion) in 2009. Moreover, the industry has been able to survive successfully amid the global financial turmoil. Government initiatives, like set up of more biotech parks and encouragement to public-private-partnerships, provided cushion to the biotech industry against tough economic conditions of recession.

Expected to grow further

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology